Daiichi Sankyo positions Asubio as discovery operation
This article was originally published in Scrip
Daiichi Sankyo is to restructure its Asubio Pharma subsidiary next year, turning it into a more tightly focused drug discovery operation in order to strengthen its in-house research.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.